MedTrace Logo

Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension

NCT05359068 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 957

Last updated 2024-05-07

No results posted yet for this study

Summary

The primary aim of the study is to assess the antihypertensive efficacy of SPH3127 in patients with mild to moderate essential hypertension.

Conditions

  • Essential Hypertension

Interventions

DRUG

SPH3127 tablet

1 tablet

DRUG

SPH3127 tablet

2 tablets

DRUG

SPH3127 tablet

4 tablets

DRUG

Valsartan

1 valsartan capsule

DRUG

SPH3127 tablet

2 tablets

DRUG

Valsartan

1 valsartan capsule

Sponsors & Collaborators

  • Shanghai Pharmaceuticals Holding Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Changsheng Ma · Beijing Anzhen Hospital, Capitcal Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-10
Primary Completion
2023-12-26
Completion
2023-12-26

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05359068 on ClinicalTrials.gov